SPRB Spruce Biosciences, Inc.
USHealthcareAs of 2026-07-08 16:00
Why SPRB matters now
Spruce Biosciences, Inc. (SPRB) is a US stock in Healthcare. The latest InvestLog snapshot shows $49.80 with -1.91% on the session and $68.3M in market capitalization; recent performance reads 1-month +8.52% and YTD -39.89%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-12.3M, and EPS of $-8.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -40.8%.
The latest indexable market news headline is "Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $145.00; recent insider activity includes Walbert Keli filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.07
P/S
0.00
EV/EBITDA
-0.69
DCF Value
$61.80
FCF Yield
-40.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-155.4%
ROA
-66.2%
ROIC
-74.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-12.3M | $-8.94 |
| Q4 2025 | $0.00 | $-14.6M | $-10.67 |
| FY 2025 | $0.00 | $-39.0M | $-50.83 |
| Q3 2025 | $0.00 | $-8.2M | $-14.58 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$174.00
Target (Median)
$145.00
Target Range
$123.00 - $283.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.20
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.